ALZAMEND NEURO INC (ALZN)

Company Profile

Alzamend Neuro Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Atlanta, Georgia and currently employs 4 full-time employees. The company went IPO on 2021-06-15. Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The firm's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's through a royalty-bearing exclusive worldwide license from the Licensor.

Company Info

ALZAMEND NEURO INC

3480 Peachtree Road NE,, Second Floor, Suite 103

Atlanta GEORGIA

P: 18447226333

CEO: Stephan Jackman

Employees: 4

Website: https://alzamend.com/